NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients

INTRODUCTION: Chronic kidney disease (CKD) has a prevalence of 9.1% globally, and frequently results in elevated serum phosphate, increasing cardiovascular morbidity and mortality risk in hemodialysis (HD) patients. DS-2330b, an oral NaPi-IIb inhibitor, reduced intestinal phosphate absorption in pre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Kidney Int Rep
Autors principals: Maruyama, Sonomi, Marbury, Thomas C., Connaire, Jeffrey, Ries, Daniel, Maxwell, William, Rambaran, Curtis
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Clinical Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938184/
https://ncbi.nlm.nih.gov/pubmed/33732982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2020.12.017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars